Cboe UK CHF

Kuros Biosciences AG (KURNZ.XC)

Compare
22.85 +3.29 (+16.82%)
As of 3:25 PM GMT. Market Open.

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CHF.
NameTitlePayExercisedYear Born
Mr. Christopher T. Fair CEO & Director 521.2k -- 1970
Mr. Daniel Geiger Chief Financial Officer -- -- 1971
Mr. Sjoerd Musters COO & GM of BV -- -- 1980
Dr. Joost D. de Bruijn B.Sc. Ph.D., Ph.D. President of Innovation and Strategy & Executive Director 572.6k -- 1966
Mr. G. Joseph Ross Senior Vice President of Marketing & Business Development -- -- 1968
Ms. Nikki Coleman Vice President of Global Human Resources -- -- --
Dr. Philippe Saudan Ph.D. Chief Development Officer -- -- 1967
Mr. John Griffin Chief Commercial Officer -- -- --
Dr. Katherine Sage D.O., FAAOS, M.S. Senior Vice President of Medical & Clinical Affairs -- -- --
Dr. Virginia Jamieson Consultant -- -- 1953

Kuros Biosciences AG

Wagistrasse 25
Schlieren, 8952
Switzerland
41 44 733 4747 https://www.kuros.ch
Sector: 
Healthcare
Industry: 
Medical Devices
Full Time Employees: 
106

Description

Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development for tissue repair and bone regeneration in the United States, the European Union, and internationally. It operates through three segments: Medical Devices, Pharmaceuticals, and Legacy Portfolio. The company offers MagnetOs Granules, an original advanced bone graft based on the submicron needle-shaped NeedleGrip surface technology; MagnetOs Putty, a mold use to fill bony voids for a predictable fusion; MagnetOs Easypack Putty, a ready-to-use mold to be implanted in any intervertebral disc space or posterolateral spine level; and Magnetos Flex Matrix, an open matrix bone graft. Its Fibrin-PTH pipeline products comprise KUR-111 and KUR-113 that are in Phase 2b clinical trials for trauma indications; KUR-113 that is in Phase 2a clinical trial for spinal indications. The company was incorporated in 2016 and is headquartered in Schlieren, Switzerland.

Corporate Governance

Kuros Biosciences AG’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

October 10, 2024 at 10:59 AM UTC

Kuros Biosciences AG Earnings Date

Recent Events